IFNGR1 and neoplasm: This suggests that DuoBody-CD3x5T4–mediated cross-linking of T cells and tumor cells still results in efficient T-cell activation but that the tumor cells lacking IFNGR1 have become less sensitive to T cell–mediated kill in a Fas-independent manner.